Alternative method for molecular Detection of SARS-CoV-2 by Lateral Flow Assay


Creative Commons License

Çam D., Gültekin E.

10th International Molecular Biology and Biotechnology Congress, Adana, Türkiye, 4 - 08 Ekim 2021, ss.69

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Adana
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayıları: ss.69
  • İnönü Üniversitesi Adresli: Evet

Özet

COVID-19 disease caused by SARS-CoV-2 emerged with Wuhan Viral Pneumonia in the late December of 2019. SARS-CoV-2 is a RNA virus and has Spike (S) protein, envelope (E) protein, membrane (M) protein and nucleocapsid (N) protein which have significance for both diagnostic and disease symptoms. N protein, especially, is a crucial for molecular diagnosis as protected protein sequence and acute immunogenicity. Since it is abundantly expressed during the infection it was chosen as reliable target sequence for molecular diagnosis by WHO and diagnosis is performed by RT-PCR. However, because of the expensive equipments and educated personel rapid tests such as lateral flow assays (LFAs) are attractive for rapid and naked eye analysis for molecular recognition and they always will be needed because of the pandemia. LFAs are point of care tests developed by antibodies and nucleic acids for rapid detection. Although lots of LFAs were reported for SARS-CoV-2 detection they are generally based on antibody detection of patients after the infection.

In this study, one hybridization model specific to N gene region for SARS-CoV-2 detection by LFA is designed. Gold nanoparticles (AuNPs) were used as label and membranes were manually sticked for designing LFAs. AuNPs were conjugated with oligonucleotides complementary to the target gene. Results showed that molecular recognition of SARS-CoV-2 by designed sandwich model in LFAs is succesfully performed and analysed with naked eye in 4-5 minutes. As a conclusion, designed model for LFA may be an alternative method for the molecular recognition of SARS-CoV-2 and might be adaptod to the other diagnosis technology like microarray, and it can be adoptable to the new mutated species of SARS-CoV-2.